KALV
KalVista Pharmaceuticals Inc (KALV)
Healthcare • NASDAQ • $26.73+0.04%
- Symbol
- KALV
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $26.73
- Daily Change
- +0.04%
- Market Cap
- $1.42B
- Trailing P/E
- N/A
- Forward P/E
- 22.27
- 52W High
- $26.85
- 52W Low
- $9.83
- Analyst Target
- $28.60
- Dividend Yield
- N/A
- Beta
- -0.12
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.
Company websiteResearch KALV on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.